Is BSLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BSLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BSLN (CHF40.25) is trading below our estimate of fair value (CHF44.09)
Significantly Below Fair Value: BSLN is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BSLN?
Key metric: As BSLN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for BSLN. This is calculated by dividing BSLN's market cap by their current
revenue.
What is BSLN's PS Ratio?
PS Ratio
3.3x
Sales
CHF 149.02m
Market Cap
CHF 487.88m
BSLN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: BSLN is good value based on its Price-To-Sales Ratio (3.3x) compared to the European Biotechs industry average (8.1x).
Price to Sales Ratio vs Fair Ratio
What is BSLN's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
BSLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
3.3x
Fair PS Ratio
1.4x
Price-To-Sales vs Fair Ratio: BSLN is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst BSLN forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
CHF 40.25
CHF 77.25
+91.9%
31.6%
CHF 120.00
CHF 52.00
n/a
6
Dec ’25
CHF 41.70
CHF 77.25
+85.3%
31.6%
CHF 120.00
CHF 52.00
n/a
6
Nov ’25
CHF 43.20
CHF 74.87
+73.3%
35.7%
CHF 120.00
CHF 44.20
n/a
6
Oct ’25
CHF 45.60
CHF 73.20
+60.5%
32.8%
CHF 110.00
CHF 44.20
n/a
6
Sep ’25
CHF 46.00
CHF 72.37
+57.3%
32.0%
CHF 110.00
CHF 44.20
n/a
6
Aug ’25
CHF 39.75
CHF 71.20
+79.1%
30.5%
CHF 105.00
CHF 44.20
n/a
6
Jul ’25
CHF 39.50
CHF 71.20
+80.3%
30.5%
CHF 105.00
CHF 44.20
n/a
6
Jun ’25
CHF 43.70
CHF 70.58
+61.5%
31.9%
CHF 105.00
CHF 40.50
n/a
6
May ’25
CHF 39.50
CHF 70.58
+78.7%
31.9%
CHF 105.00
CHF 40.50
n/a
6
Apr ’25
CHF 37.65
CHF 69.08
+83.5%
30.6%
CHF 105.00
CHF 40.50
n/a
6
Mar ’25
CHF 35.15
CHF 69.08
+96.5%
30.6%
CHF 105.00
CHF 40.50
n/a
6
Feb ’25
CHF 33.05
CHF 64.38
+94.8%
24.7%
CHF 85.00
CHF 40.50
n/a
4
Jan ’25
CHF 35.30
CHF 70.70
+100.3%
26.5%
CHF 91.00
CHF 40.50
n/a
5
Dec ’24
CHF 34.95
CHF 75.68
+116.5%
19.8%
CHF 91.00
CHF 57.70
CHF 41.70
4
Nov ’24
CHF 35.60
CHF 73.28
+105.9%
20.1%
CHF 91.00
CHF 52.00
CHF 43.20
6
Oct ’24
CHF 41.00
CHF 70.44
+71.8%
21.7%
CHF 91.00
CHF 52.00
CHF 45.60
7
Sep ’24
CHF 48.20
CHF 70.44
+46.1%
21.7%
CHF 91.00
CHF 52.00
CHF 46.00
7
Aug ’24
CHF 43.85
CHF 70.44
+60.6%
21.7%
CHF 91.00
CHF 52.00
CHF 39.75
7
Jul ’24
CHF 42.25
CHF 67.18
+59.0%
21.0%
CHF 91.00
CHF 52.00
CHF 39.50
6
Jun ’24
CHF 45.90
CHF 67.18
+46.4%
21.0%
CHF 91.00
CHF 52.00
CHF 43.70
6
May ’24
CHF 43.20
CHF 72.07
+66.8%
20.8%
CHF 91.00
CHF 52.00
CHF 39.50
6
Apr ’24
CHF 50.10
CHF 74.80
+49.3%
18.4%
CHF 91.00
CHF 52.00
CHF 37.65
5
Mar ’24
CHF 52.40
CHF 68.98
+31.6%
26.2%
CHF 91.00
CHF 39.90
CHF 35.15
6
Feb ’24
CHF 49.00
CHF 73.82
+50.6%
34.7%
CHF 120.00
CHF 39.90
CHF 33.05
6
Jan ’24
CHF 45.80
CHF 69.15
+51.0%
26.2%
CHF 91.00
CHF 39.90
CHF 35.30
6
Dec ’23
CHF 49.75
CHF 68.58
+37.8%
28.9%
CHF 91.00
CHF 39.90
CHF 34.95
5
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.